代谢综合征及其药物治疗与去势抵抗性前列腺癌发生时间的关联
研究纳入1996至2014年在本机构接受一线雄激素剥夺治疗(ADT)的409例转移性去势敏感性前列腺癌男性,评估代谢综合征及其药物治疗与去势抵抗性前列腺癌(CRPC)发生时间的关联。中位随访59个月,87%(356例)进展为CRPC,中位至CRPC时间19个月,56%符合代谢综合征定义。控制人口学和前列腺癌特异性变量后,代谢综合征与更短的至CRPC时间相关(HR 1.41,95%CI 1.09-1.81);在代谢综合征男性中,他汀使用与更慢的CRPC进展相关(HR 0.70,95%CI 0.49-0.98)。
要点
- 代谢综合征与更短的至CRPC时间相关(HR 1.41,95%CI 1.09-1.81)。
- 代谢综合征男性中,他汀使用与更慢的CRPC进展相关(HR 0.70,95%CI 0.49-0.98)。
- 中位随访59个月,87%(356/409)进展为CRPC,中位至CRPC时间19个月。
核心结论
- 研究提示代谢综合征是去势敏感性前列腺癌更早进展为去势抵抗性前列腺癌的风险因素,并提出他汀使用等治疗可能延缓进展时间的可能性。
研究设计与样本
- 研究纳入1996至2014年在本机构接受一线ADT的409例转移性去势敏感性前列腺癌男性。
- 从病历中收集ADT开始时代谢综合征、他汀使用、阿司匹林使用和二甲双胍使用信息。
- 至CRPC时间定义为开始ADT至基于前列腺癌工作组3定义诊断CRPC的持续时间。
- 采用灵活参数生存模型计算代谢状况与ADT开始至CRPC时间关联的风险比(HR)和95%置信区间(CI)。
主要发现
- 中位随访59个月,87%(N=356)男性进展为CRPC,中位至CRPC时间为19个月。
- 56%男性符合代谢综合征定义。
- 控制人口学和前列腺癌特异性变量后,代谢综合征与更短的至CRPC时间相关(HR 1.41,95%CI 1.09-1.81)。
- 在代谢综合征男性中,他汀使用与更慢的CRPC进展相关(HR 0.70,95%CI 0.49-0.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic syndrome and its pharmacologic treatment can potentially influence the progression of prostate cancer in men receiving androgen deprivation therapy (ADT). We aimed to evaluate the association between metabolic syndrome and its pharmacologic treatment with time to castration-resistant prostate cancer (CRPC). METHODS: We identified 409 men with metastatic castration-sensitive prostate cancer receiving first line ADT from 1996 to 2014 at our institution. Information concerning metabolic syndrome, statin use, aspirin use, and metformin use at initiation of ADT was collected from medical records. Time to CRPC was defined as the duration between initiating ADT and diagnosis of CRPC based on the Prostate Cancer Working Group 3 definition. Flexible parametric survival models were used to calculate hazard ratios (HR, and 95% confidence intervals, CI) of the association between metabolic conditions and time from ADT initiation to CRPC. RESULTS: During a median follow-up of 59 months, 87% (N = 356) men progressed to CRPC. Median time to CRPC was 19 months. Fifty-six percent of men met the definition of metabolic syndrome. Controlling for demographic and prostate cancer-specific variables, metabolic syndrome was associated with shorter time to CRPC (HR 1.41, 95% CI 1.09-1.81). Importantly, in men with metabolic syndrome, statin use was associated with a slower progression to CRPC (HR 0.70, 95% CI 0.49-0.98). CONCLUSIONS: Our study suggests that metabolic syndrome is a risk factor for earlier progression from castration-sensitive to castration-resistant prostate cancer and raises the possibility that treatment, such as statin use, may slow the time to progression.
引用
- Geng JH, Plym A, Penney KL, et al. Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 35075214. doi:10.1038/s41391-022-00494-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。